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Abstract
Introduction: Total cholesterol (TC) and blood pressure (BP) are likely to take a dynamic course over time in patients 
with systemic lupus erythematosus (SLE). This would have important implications in terms of using single-point-in-
time measurements of these variables to assess coronary artery disease (CAD) risk. The objective of this study was to 
describe and quantify variability over time of TC and BP among patients with SLE and to determine their correlates.
Methods: Patients in the Toronto lupus cohort who had two or more serial measurements of TC and systolic and 
diastolic BP (SBP and DBP) were included in the analysis. Variability over time was described in terms of the proportion 
of patients whose TC and BP profile fluctuated between normal and elevated (TC > 5.2 mmol/L; SBP ≥ 140 mm Hg or 
DBP ≥ 90 mm Hg), and also in terms of within- and between-patient variance quantified by using analysis of variance 
modeling. Generalized estimating equations (GEEs) were used to determine independent correlates of each of TC, SBP, 
and DBP, treated as continuous outcome variables.
Results: In total, 1,260 patients, comprising 26,267 measurements of each of TC, SBP, and DBP, were included. Mean ± 
SD number of measurements per patient was 20.8 ± 20. Mean ± SD time interval between measurements was 5.4 ± 9.7 
months. Mean ± SD time interval from the start to the end of the study was 9.3 ± 8.5 years. Over time, 64.7% of patients 
varied between having normal and elevated cholesterol levels, whereas the status of 46.4% of patients varied between 
normotensive and hypertensive. By using analysis of variance (ANOVA), the within-patient percentage of total variance 
for each of TC, SBP, and DBP was 48.2%, 51.2%, and 63.9%, respectively. By using GEE, independent correlates of TC and 
BP included age, disease activity, and corticosteroids; antimalarial use was negatively correlated with TC (all P values < 
0.0001).
Conclusions: TC and BP vary markedly over time in patients with SLE. This variability is due not only to lipid-lowering 
and antihypertensive medications, but also to disease- and treatment-related factors such as disease activity, 
corticosteroids, and antimalarials. The dynamic nature of TC and BP in SLE makes a compelling case for deriving 
summary measures that better capture cumulative exposure to these risk factors.
Introduction
Systemic lupus erythematosus (SLE) is strongly associ-
ated with premature atherosclerotic CAD [1,2]. Indeed,
young women aged 35 to 44 years are > 50 times more
likely to have myocardial infarction than are their age-
matched peers [3]. One in 10 patients with SLE is diag-
nosed with clinical CAD, making this complication one of
the leading causes of morbidity and mortality in SLE
[4,5]. Whilst traditional cardiovascular risk factors only
p a r t l y  a c c o u n t  f o r  t h e  i n c r e a s e d  r i s k  o f  C A D  i n  S L E ,
many of these risk factors are potentially treatable [6].
Hypercholesterolemia and hypertension are two tradi-
tional cardiac risk factors that have been shown to be
independently predictive of coronary events in patients
with SLE when measured at the first available visit ('base-
line') or defined as 'abnormal ever' during follow-up
[3,4,7]. However, to date, the magnitude of risk associated
with these risk factors may not have been accurately esti-
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mated by using approaches that fail to take into account
the possible variability of these risk factors over time.
Evidence suggests that in the first 3 years of disease, one
third of patients with SLE have 'variable hypercholester-
olemia', with cholesterol levels that fluctuate between
'normal' and 'abnormal', which, in this case, is defined as
total serum cholesterol > 5.2 mmol/L [8]. Similarly, in the
general population, systolic and diastolic blood pressure
have been shown to vary over time, a phenomenon that
likely also affects SLE patients in whom both disease
manifestations and treatments may affect blood pressure
[9-11]. To date, the variability over time of TC, SBP, and
DBP over the course of disease in patients with SLE has
not been rigorously evaluated. The objective of this study
was to describe and quantify variability over time of TC,
SBP, and DBP and to determine their correlates in
patients with SLE. We used > 26,000 measurements of
each of TC, SBP, and DBP taken in > 1,200 SLE patients,
in > 9 years of follow-up. In assessment of variability over
time, we defined each of TC, SBP, and DBP dichoto-
mously and as continuous variables. Generalized estimat-
ing equations (GEEs) were used to determine
independent correlates of TC, SBP, and DBP over time.
Materials and methods
Patients
Among the University of Toronto lupus cohort, patients
who had two or more serial measurements of TC, SBP,
and DBP were included in the analysis. Patients attending
the University of Toronto lupus clinic are followed up at
2- to 6-month intervals, and clinical and laboratory data
obtained at each visit are stored in a dedicated database.
All patients fulfill four or more of the ACR classification
criteria for SLE, or have three criteria and a typical lesion
of SLE on renal or skin biopsy [12,13]. Collection and
storage of data are approved by the research ethics board
of the University Health Network, and patients give
informed consent on entry into the clinic.
Methods
TC, SBP, and DBP and 'other' variables
In addition to TC, SBP, and DBP, data on patients' demo-
graphic profiles (including age, sex, menopausal status,
and race), disease duration, disease activity, medications,
intercurrent infections, smoking, and diabetes were rou-
tinely collected according to a set protocol. The data were
stored and tracked in the lupus database at each clinic
visit for the period from entry into the clinic up to the
most recent visit as of August 2008. Each measurement of
TC, SBP, and DBP was therefore tied to a clinic visit. We
used only visits wherein all of three of TC, SBP, and DBP
had been measured and recorded.
Definitions of variables Age and disease duration at the
time of each visit were reported in years. Disease dura-
tion was calculated from the date of physician diagnosis
of SLE to the date of each visit. Disease activity at each
visit was reported by using the SLE Disease Activity
Index 2000 (SLEDAI-2K), wherein scores range from 0 to
105, with higher scores indicating more-active disease
[14]. Corticosteroid, antimalarial, and immunosuppres-
sive use at each visit were reported categorically, irre-
spective of dose. Antimalarials included chloroquine and
hydroxychloroquine. Immunosuppressives included
methotrexate, azathioprine, mycophenolate mofetil,
cyclosporine, and cyclophosphamide. Antihypertensives
included all classes of drugs used to reduce blood pres-
sure. Lipid-lowering medications were predominantly
'statins.' Antihypertensive and lipid-lowering therapy at
each visit was defined categorically. TC level was mea-
sured nonfasting in plasma by using a commercial assay
(kit 236691; Boehringer Mannheim, Indianapolis, IN) at
each visit and recorded in millimoles per liter (mmol/L).
It has been shown that only small, clinically insignificant
differences in cholesterol level are found when measured
in the fasting or nonfasting state [15].
Hypercholesterolemia was defined as total plasma cho-
lesterol > 5.2 mmol/L [8,16]. SBP and DBP were mea-
sured in millimeters of mercury (mm Hg) at each visit by
using a manual sphygmomanometer. Hypertension was
defined as DBP ≥ 90 or SBP ≥ 140 mm Hg [17]. Diabetes
was defined as fasting plasma glucose > 7.0 mmol/L or
diabetes therapy. Menopause was defined as a minimum
of 12 months of amenorrhea, irrespective of cause. Hor-
mone-replacement therapy was defined as treatment
with estrogen with or without progestin.
Statistical analysis
Characteristics of patients in the study as well as the total
number, frequency, and values of TC, SBP, and DBP mea-
surements are described. The proportion of patients with
'normal' or 'elevated' TC, SBP, and DBP at study entry and
during follow-up was determined. 'Method of moments'
analysis of variance (ANOVA) modeling was used to
quantify total, within-, and between-patient variance in
TC, SBP, and DBP, each treated as a continuous variable.
Linear regression modeling with analysis of repeated
measures was performed by using GEE to determine the
independent correlates of each of TC, SBP, and DBP ('out-
come' variables). Predictor/independent variables ('cova-
riates') included sex, age, disease duration, SLEDAI-2K
score, infection, diabetes, smoking, and treatment with
corticosteroids, antimalarials, immunosuppressives, anti-
hypertensives, and lipid-lowering medications. For each
covariate, the measurements used were those recorded at
the time of (that is, 'coincident') with each measurement
of SBP or DBP.
In the model used to determine correlates of TC,
hypertension was also included as a covariate, whereas inNikpour et al. Arthritis Research & Therapy 2010, 12:R125
http://arthritis-research.com/content/12/3/R125
Page 3 of 9
the models used to determine correlates of SBP and DBP,
hypercholesterolemia was also included as a covariate.
Modeling was repeated by using only female patients. In
these models, in addition to the aforementioned indepen-
dent variables, menopausal status and hormone-replace-
ment therapy were also included as covariates.
All statistical analyses were performed by using SAS
version 9.1 (SAS Institute Inc., Cary, NC).
Results
In total, 1,260 patients were included in the analysis,
comprising 26,267 measurements of each of TC, SBP, and
DBP. The characteristics of these patients are summa-
rized in Table 1. The patients were mostly female (88.3%)
and white (73%). Among the female patients, 224 (20.1%)
were menopausal at study entry, and 445 (40.0%) were
menopausal either at study entry or during follow-up.
Mean ± standard deviation (SD) age at first clinic visit
and at entry to study were 35.0 ± 13.6 and 35.4 ± 13.7
years, respectively. In 80% of patients, the first clinic visit
was also the entry visit into the study. Mean ± SD disease
duration at first clinic visit and at entry to study were 4.0
± 5.0 and 4.4 ± 6.0 years, respectively. Among the
patients, 42% had their first study visit within 12 months
of diagnosis ('inception cohort'). Among noninception
patients, at the first study visit, mean ± SD disease dura-
tion was 7.3 ± 6.4 years, ranging from 1 to 52 years. Mean
± SD SLEDAI-2K score at first clinic visit and at entry to
study were 9.6 ± 7.7 and 8.7 ± 7.0, respectively, indicating
moderate disease activity.
The total number, frequency, and values of TC, SBP,
and DBP measurements are reported in Table 2. For each
of TC, SBP, and DBP, the mean ± SD and median number
of measurements per patient were 20.8 ± 20.8 and 14,
respectively. The mean ± SD and median time interval
between measurements were 5.6 ± 9.7 and 3.7 months,
respectively. The mean ± SD and median time interval
from the start to the end of the study were 9.3 ± 8.5 and
6.5 years, respectively. The mean ± SD level of TC at the
start of study was 5.2 ± 1.7 mmol/L. The mean ± SD level
of SBP at the start of the study was 123 ± 19.2 mm Hg.
The mean ± SD level of DBP at the start of study was 77.2
± 12.0 mm Hg.
The proportion of patients with normal (or elevated)
TC or BP at the start of the study and during follow-up is
reported in Table 3. Of note, over time, 64.7% of patients
varied between having normal and elevated TC levels,
with hypercholesterolemia recorded for 36% of the total
number of visits. Likewise, the status of 46.4% of patients
varied between normotensive and hypertensive, with
hypertension recorded for 14% of the total number of
visits.
The total and the within- and between-patient variance
in TC, SBP, and DBP determined by using method of
moments ANOVA is reported in Table 4. In this analysis,
the TC, the SBP, and the DBP were treated as continuous
variables. In the case of TC, 51.8% of the total variance
was attributable to variance between patients, whereas
48.2% of the total variance was seen within individuals.
For SBP, 48.8% of the total variance was due to variance
Table 1: Characteristics of patients (n = 1,260)
Characteristic Number (%) or mean ± SD
Female 1,113 (88.3%)
Menopausal at entry to studya 224 (20.1%)
Menopausal during follow-upa 445 (40.0%)
Race: White 880 (73%)
Black 119 (10%)
Asian 113 (9%)
Other 96 (8%)
Age at first clinic visit (years) 35.0 ± 13.6
Disease duration at first clinic visit 
(years)
4.0 ± 5.0
SLEDAI-2K at first clinic visitb 9.6 ± 7.7
Age at entry to study (years) 35.4 ± 13.7
Disease duration at entry to study 
(years)
4.4 ± 6.0
SLEDAI-2K at entry to studyb 8.7 ± 7.0
Hypertension at entry to studyc 190 (15.1%)
Hypercholesterolemia at entry to 
studye
528 (41.9%)
Diabetes at entry to studyf 30 of 1,223 (2.5%)d
Smoker at entry to studyg 247 of 1,235 (20.0%)d
Corticosteroid use at entry to study 763 of 1,257 (60.7%)d
Antimalarial use at entry to studyh 462 of 1,256 (36.8%)d
Immunosuppressive use at entry to 
studyi
259 of 1,255 (20.6%)d
SD, standard deviation.
aMenopause defined as a minimum of 12 months of amenorrhea, 
irrespective of cause.
bScores range from 0 to 105, with higher scores indicating more-
active disease.
cDiastolic BP ≥ 90 or systolic BP ≥ 140 mm Hg.
dFor these variables, data were incomplete for a small number of 
patients. The denominator of the fractions in the second column is 
the total number of patients from whom the percentage was 
calculated.
eHypercholesterolemia was defined as cholesterol > 5.2 mmol/L.
fDiabetes was defined as fasting plasma glucose > 7.0 mmol/L or 
diabetes therapy.
gSmoking one or more cigarettes per day.
hAntimalarials include chloroquine and hydroxychloroquine.
iImmunosuppressives include methotrexate, azathioprine, 
mycophenolate mofetil,
cyclosporine, and cyclophosphamide.Nikpour et al. Arthritis Research & Therapy 2010, 12:R125
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between patients, whereas 51.2% of the total variance was
seen within patients. Similarly for DBP, between-patient
variance comprised 36.1% of the total variance, whereas
with-in patient variance accounted for 63.9% of the total
variance.
Linear-regression modeling with repeated measures
analysis using GEE revealed several independent corre-
lates of TC (Table 5): coincident age (parameter estimate,
0.009; 95% confidence interval (CI) 0.004 to 0.014; P =
0.0005), coincident SLEDAI-2K score (parameter esti-
mate, 0.04; 95% CI, 0.03 to 0.05; P < 0.0001); coincident
corticosteroid use (parameter estimate, 0.32; 95% CI, 0.22
to 0.42; P < 0.0001); coincident use of immunosuppres-
sives (parameter estimate, 0.17; 95% CI, 0.06 to 0.27; P =
0.0017); coincident use of antihypertensives (parameter
estimate, 0.19; 95% CI, 0.08 to 0.30; P = 0.0009); and coin-
cident hypertension (parameter estimate, 0.34; 95% CI,
0.22 to 0.46; P < 0.0001). Coincident use of antimalarials
was negatively correlated with TC (parameter estimate, -
0.42; 95% CI, -0.53 to -0.32; P < 0.0001). When the model
was run with only female patients (Table 6), in addition to
the variables listed, another independent correlate of TC
was coincident hormone-replacement therapy (parame-
ter estimate, 0.17; 95% CI, 0.09 to 0.25; P < 0.0001). A
trend toward a significant association with menopausal
status was noted (P = 0.089). Disease duration (parameter
estimate, -0.004; 95% CI, -0.006 to -0.0017; P = 0.0008)
and coincident lipid-lowering therapy (parameter esti-
mate, -0.09; 95% CI, -0.15 to -0.03; P = 0.004) were nega-
tively correlated with TC.
Independent correlates of SBP determined by using
GEE are listed in Table 7. Overall SBP was independently
correlated with coincident age (parameter estimate, 0.41;
95% CI, 0.35 to 0.48; P  < 0.0001), SLEDAI-2K score
(parameter estimate, 0.39; 95% CI, 0.28 to 0.50; P  <
0.0001), use of antihypertensives (parameter estimate,
6.44; 95% CI, 4.94 to 7.94; P < 0.0001), and hypercholes-
terolemia (parameter estimate, 3.78; 95% CI, 2.50 to 5.05;
P < 0.0001). When the model was run using only female
patients (Table 8), in addition to these variables, other
independent correlates of SBP were diabetes (parameter
estimate, 2.43; 95% CI, 1.16 to 3.70; P = 0.0002) and coin-
cident smoking (parameter estimate, 1.12; 95% CI, 0.20 to
2.04; P = 0.017). A trend was noted toward a significant
association with menopausal status (P = 0.0927). Coinci-
dent use of antimalarials (parameter estimate, -1.32; 95%
CI, -1.96 to -0.69; P  < 0.0001), immunosuppressives
(parameter estimate, -1.81; 95% CI, -2.48 to -1.13; P <
0.0001) and lipid-lowering therapy (parameter estimate, -
1.62; 95% CI, -2.52 to -0.73; P = 0.0004) were negatively
correlated with SBP.
Independent correlates of DBP determined by using
GEE overall mirrored those of SBP. DBP was indepen-
dently correlated with coincident age (parameter esti-
Table 2: Number, frequency, and values of total cholesterol (TC), systolic blood pressure (SBP), and diastolic blood 
pressure (DBP) measurements
Mean ± SD Min, Max Median
Number of measurements per patient 20.8 ± 20.8 2, 124 14
Time interval between visits (months) 5.6 ± 9.7 0.13, 338.3 3.7
Time from study start to end (years) 9.3 ± 8.5 0.1, 35.0 6.5
TC at start of study (mmol/L) 5.2 ± 1.7 1.1, 16.1 4.9
SBP at start of study (mm Hg) 123 ± 19.2 80, 220 120
DBP at start of study (mm Hg) 77.2 ± 12.0 55, 180 80
SD, standard deviation; Min, Max, minimum and maximum.
Table 3: Proportion of patients with normal and elevateda total cholesterol (TC), systolic blood pressure (SBP), and 
diastolic blood pressure (DBP) at baseline and during follow-up
Variable Elevated at study start
n (%)
Persistently normal
n (%)
Persistently elevated
n (%)
Varying
n (%)
Visits elevated (%)
TCa 528 (41.9) 334 (26.5) 111 (8.8) 815 (64.7) 36
SBP (mm Hg) 153 (12.1) 725 (58.0) 15 (1.2) 520 (41.3) 12
DBP (mm Hg) 114 (9.1) 804 (64.0) 7 (0.6) 449 (35.6) 7
BP (mm Hg) 190 (15.1) 654 (51.9) 21 (1.7) 585 (46.4) 14
aElevated TC is defined as > 5.2 mmol/L. Elevated SBP is defined as ≥ 140 mm Hg. Elevated DBP is defined as ≥ 90 mm Hg. Elevated BP is defined 
as either SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg.Nikpour et al. Arthritis Research & Therapy 2010, 12:R125
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mate, 0.08; 95% CI, 0.04 to 0.11; P = 0.0001), SLEDAI-2K
score (parameter estimate, 0.23; 95% CI, 0.16 to 0.30; P <
0.0001), coincident use of antihypertensives (parameter
estimate, 3.75; 95% CI, 2.83 to 4.66; P < 0.0001) and coin-
cident hypercholesterolemia (parameter estimate, 2.60;
95% CI, 1.83 to 3.38; P < 0.0001). When the model was
run using only female patients, in addition to these vari-
ables, coincident disease duration (parameter estimate,
0.03; 95% CI, 0.01 to 0.05; P = 0.008) also was indepen-
dently correlated with DBP. Coincident use of antimalari-
als (parameter estimate, -0.94; 95% CI, -1.36 to -0.52; P <
0.0001), immunosuppressives (parameter estimates, -
0.50; 95% CI, -0.94 to -0.05; P = 0.028), and lipid-lowering
therapy (parameter estimate, -1.13; 95% CI, -1.72 to -0.53;
P = 0.0002) were negatively correlated with DBP.
Discussion
This study revealed substantial changes in TC, SBP, and
DBP level over time among patients with SLE. Multivari-
ate regression analysis using GEE showed an association
of TC, SBP, and DBP, not only with lipid-lowering and
antihypertensive therapy, but also with lupus activity and
medications and other cardiovascular risk factors.
This study of variability and correlates of TC and BP
was based on numerous (on average, 20) and frequent (on
average, every 5.6 months) measurements of these vari-
ables in 1,260 patients with SLE, followed up on average
for 9.3 years. In total, a large dataset of 26,267 individual
data points was used in analysis of variability and corre-
lates for TC, SBP, and DBP.
We chose to report 'variability' in serial measurements
taken over time in two ways. First, TC, SBP, and DBP each
were dichotomized into 'normal' and 'elevated' values
based on conventional cut points, and over time, the pro-
portion of patients in whom values fluctuated from one
category to another was determined. Second, with TC,
SBP, and DBP treated as continuous variables, total vari-
ance in each variable was quantified and dissected into
within- and between-patient variance by using ANOVA
modeling. The latter approach eliminates the need to
dichotomize TC and BP values according to cut points,
which, although based on evidence, are somewhat arbi-
trary. Common to both methods is the assessment of
change in mean or average values over time. However, it
must be borne in mind that this approach does not cap-
ture the trajectory taken by each variable measured seri-
ally in each patient.
In this study, over a mean and median follow-up period
of 9.3 and 6.5 years, respectively, 8.8% of patients had per-
sistent hypercholesterolemia, whereas almost two thirds
(64.7%) had variable hypercholesterolemia. This is even
greater variability over time than previously reported in
SLE patients in the first 3 years of disease, wherein one
third of patients had persistent hypercholesterolemia,
whereas one third had variable hypercholesterolemia [8].
The greater variability and fewer cases of persistent ele-
vation in cholesterol may be due to fluctuations in disease
activity over time and the effect of changes to therapy,
including the use of corticosteroids and lipid-lowering
agents. Furthermore, the longer follow-up in the present
study means greater potential for the recording of change
over time, irrespective of cause. Certainly the variation in
cholesterol over time among patients with SLE far
Table 4: Total, between-, and within-patient variance in total cholesterol (TC), systolic blood pressure (SBP), and diastolic 
blood pressure (DBP) during follow-up
Total variance Between-patient 
variance
Within-patient 
variance
Variance between
 patients (%)
Variance within 
patients (%)
TC (mmol/L) 1.9 0.97 0.91 51.8 48.2
SBP (mm Hg) 347.3 169.6 177.7 48.8 51.2
DBP (mm Hg) 119.2 43.1 76.1 36.1 63.9
Table 5: Independent correlates of total cholesterol 
determined by using multivariate linear regression (GEE)
Variablea Parameter 
estimate
95% CI P value
Age (years) 0.009 0.004, 0.014 0.0005
SLEDAI-2K scoreb 0.04 0.03, 0.05 < 0.0001
Corticosteroids 0.32 0.22, 0.42 < 0.0001
Antimalarialsc -0.42 -0.53, -0.32 < 0.0001
Immunosuppressivesd 0.17 0.06, 0.27 0.0017
Antihypertensivese 0.19 0.08, 0.30 0.0009
Hypertensionf 0.34 0.22, 0.46 < 0.0001
GEE, generalized estimating equation; CI, confidence interval.
aAll variables measured coincident with measurement of total 
cholesterol.
bSLE Disease Activity Index 2000; scores range from 0 to 105, with 
higher scores indicating more-active disease.
cAntimalarials include chloroquine and hydroxychloroquine.
d Immunosuppressives include methotrexate, azathioprine, 
mycophenolate mofetil,
cyclosporine, and cyclophosphamide.
eAntihypertensives include all classes of drugs used to lower blood 
pressure.
fHypertension is defined as systolic BP ≥ 140 mm Hg or diastolic BP ≥ 
90 mm Hg.Nikpour et al. Arthritis Research & Therapy 2010, 12:R125
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exceeds that reported for the general population, in
whom, in the absence of treatment, cholesterol levels
tend to be relatively stable over time [18,19].
Likewise, almost half (46.4%) of all patients in this study
had varying hypertension over the duration of the study,
whereas only 1.7% had persistent hypertension. Although
no previous studies exist with which to compare the pro-
portion of SLE patients who have persistent and variable
hypertension, the findings of this study support our origi-
nal hypothesis that BP likely takes a variable course in
patients with SLE.
The absolute total variance in TC and BP is reported in
Table 4. The magnitude of total variance for TC is much
smaller than that for SBP and DBP, reflecting the smaller
range of possible values for the former. In addition, TC
measurements may be inherently less variable over time
for physiological reasons and also because TC is mea-
sured in a laboratory by using standardized assays that
have small interassay variation [20]. Conversely, blood
pressure measurements are subject to measurement error
by physicians and volatility because of the phenomenon
of 'white-coat hypertension.' Sequential studies in the
general population have shown that BP can decrease by
an average of 10 to 15 mm Hg between clinic visits [9,10].
Thus, many patients considered to be hypertensive at ini-
tial visits to a clinic turn out to be normotensive. To date,
no studies have directly compared blood-pressure vari-
Table 6: Independent correlates of total cholesterol in women only, determined by using multivariate linear regression 
(GEE)
Variablea Parameter estimate 95% CI P value
Age (years) 0.009 0.006, 0.011 < 0.0001
SLEDAI-2K scoreb 0.04 0.036, 0.046 < 0.0001
Disease duration (years) -0.004 -0.006, -0.0017 0.0008
Corticosteroids 0.31 0.26, 0.36 < 0.0001
Antimalarialsc -0.41 -0.45, -0.36 < 0.0001
Immunosuppressivesd 0.15 0.11, 0.20 < 0.0001
Antihypertensivese 0.19 0.14, 0.24 < 0.0001
Hypertensionf 0.25 0.19, 0.32 < 0.0001
Lipid-lowering meds (statins) -0.09 -0.15, -0.03 0.004
HRTg 0.17 0.09, 0.25 < 0.0001
GEE, generalized estimating equation; CI, confidence interval.
aAll variables measured coincident with measurement of total cholesterol.
bSLE Disease Activity Index 2000; scores range from 0 to 105, with higher scores indicating more-active disease.
cAntimalarials include chloroquine and hydroxychloroquine.
d Immunosuppressives include methotrexate, azathioprine, mycophenolate mofetil,
cyclosporine, and cyclophosphamide.
eAntihypertensives include all classes of drugs used to lower blood pressure.
fHypertension is defined as systolic BP ≥ 140 mm Hg or diastolic BP ≥ 90 mm Hg.
gEstrogen with/without progestin hormone-replacement therapy.
Table 7: Independent correlates of systolic blood pressure determined by using multivariate linear regression (GEE)
Variable Parameter estimate 95% CI P value
Age (years) 0.41 0.35, 0.48 < 0.0001
SLEDAI-2K scorea 0.39 0.28, 0.50 < 0.0001
Antihypertensives 6.44 4.94, 7.94 < 0.0001
Hypercholesterolemia 3.78 2.50, 5.05 < 0.0001
GEE, generalized estimating equations; CI, confidence interval.
All variables were measured coincident with measurement of total cholesterol.
aSLE Disease Activity Index 2000; scores range from 0 to 105, with higher scores indicating more-active disease.
Antihypertensives include all classes of drugs used to lower blood pressure.
Hypercholesterolemia defined as total plasma cholesterol > 5.2 mmol/L.Nikpour et al. Arthritis Research & Therapy 2010, 12:R125
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ability over time in SLE patients with healthy population
controls.
Previous studies evaluated the role of TC and BP as pre-
dictors of atherosclerotic coronary events in SLE; this is
the first study to look at these risk factors as 'outcome'
variables and to seek to determine their independent cor-
relates. The importance of this approach is twofold. First,
this type of analysis provides insight into the reasons for
the pronounced variability over time of these cardiac risk
factors in SLE. Second, identifying correlates of TC and
BP in SLE aids in the selection of covariates and interac-
tion terms for inclusion in multivariate models when the
outcome of interest is atherosclerotic coronary events.
In our analyses, we used GEE to allow adjustment for
the expected correlation between repeated measures over
time within individuals ('fixed effects'). These models
have shown significant associations between increasing
age and each of TC, SBP, and DBP. The association
between older age and elevation in lipid levels and blood
pressure is well described in the general population
[21,22]. Our models have also shown that greater disease
activity at the time of measurement is independently
associated with higher TC, SBP , and DBP . This is a very
important observation. Borba et al. [23] previously noted
a significant correlation between SLEDAI scores and all
lipid subfractions, including TC, as well as an 'active
lupus pattern' of dyslipidemia in times of disease activity.
Although we found that use of immunosuppressives
was significantly and independently associated with ele-
vated TC, it is unlikely that hypercholesterolemia is a
direct effect of treatment with these agents. Rather,
immunosuppressive use is likely a surrogate for persistent
low-grade disease activity that may not be adequately
captured by the SLEDAI-2K scoring system. Notably,
coincident use of immunosuppressives was negatively
a s s o c i a t e d  w i t h  b o t h  S B P  a n d  D B P ,  i n d i c a t i n g  t h a t
although greater disease activity is associated with higher
BP, control of disease activity is associated with a reduc-
tion in BP.
The findings of this study support the long-suspected
independent association between hypercholesterolemia
and hypertension in SLE [24]. In this study, hypertension
and treatment with antihypertensives were significantly
associated with TC, whereas hypercholesterolemia and
lipid-lowering therapy were significantly correlated with
both SBP and DBP. This association highlights the phe-
nomenon of 'clustering' of traditional cardiac risk factors
within individuals with SLE and stresses the need for
screening for additional cardiac risk factors when one or
more risk factors are present.
As shown in previous studies, concomitant use of anti-
malarials was associated with lower levels of TC. Reduc-
tion in plasma cholesterol level is one of the direct
pharmacologic effects of antimalarials in patients with
Table 8: Independent correlates of systolic blood pressure in women only, determined by using multivariate linear 
regression (GEE)
Variable Parameter estimate 95% CI P value
Age (years) 0.44 0.40, 0.48 < 0.0001
SLEDAI-2K scorea 0.37 0.30, 0.44 < 0.0001
Antimalarialsb -1.32 -1.96, -0.69 < 0.0001
Immunosuppressivesc -1.81 -2.48, -1.13 < 0.0001
Antihypertensivesd 6.85 6.17, 7.53 < 0.0001
Diabetese  2.43 1.16, 3.70 0.0002
Smokingf 1.12 0.20, 2.04 0.017
Hypercholesterolemiag 3.10 2.41, 3.78 < 0.0001
Lipid-lowering meds (statins) -1.62 -2.52, -0.73 0.0004
GEE, generalized estimating equations; CI, confidence interval.
All variables were measured coincident with measurement of total cholesterol.
aSLE Disease Activity Index 2000; scores range from 0 to 105, with higher scores indicating more-active disease.
bAntimalarials include chloroquine and hydroxychloroquine.
cImmunosuppressives include methotrexate, azathioprine, mycophenolate mofetil,
cyclosporine, and cyclophosphamide.
dAntihypertensives include all classes of drugs used to lower blood pressure.
eDiabetes is defined as fasting plasma glucose > 7.0 mmol/L or diabetes therapy.
fSmoking one or more cigarettes per day.
gHypercholesterolemia defined as total plasma cholesterol > 5.2 mmol/L.Nikpour et al. Arthritis Research & Therapy 2010, 12:R125
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SLE [25-27]. In this study, antimalarial use was also asso-
ciated with lower levels of both SBP and DBP . How-
ever, a reduction in BP is not known to be a direct
pharmacologic effect of this class of drugs. More likely,
this association again points to the link between hyperc-
holesterolemia and hypertension in SLE. Further support
for this link was manifest in the association between
lipid-lowering therapy and both reduced TC and BP. This
observation also suggests that lipid-lowering therapy may
have beneficial effects in patients with SLE, independent
of a reduction in cholesterol level. However, the role of
lipid-lowering therapy in prevention of atherosclerotic
events in SLE can be definitively assessed only in an inter-
vention study.
Among women with SLE, other independent correlates
of TC and BP were current smoking and hormone-
replacement therapy. However, our analyses were limited
by lack of data on pack-years of smoking [28]. The associ-
ation between smoking and hypercholesterolemia has
been well described in the general population, and now,
in this study, it also has been demonstrated in women
with SLE [29]. In the general population, smoking also is
associated with hypertension, in particular, with elevated
SBP, an association that also was found in this study of
patients with SLE [30]. Although among postmenopausal
women, estrogen has been shown to have a beneficial
effect on serum lipid concentrations, progestin contained
in most standard HRT regimens partly negates this effect
[28,31,32]. The net result of these opposing effects is
dependent on the patient's age and overall cardiovascular
risk profile. The association between diabetes and BP
seen here in women with SLE has been well described in
the general population [33].
The link between longer disease duration and higher
TC and DBP suggests that the accrual of cardiac risk fac-
tors occurs over the course of disease and is consistent
with the concept that chronic inflammation contributes
to cardiac risk through association with traditional risk
factors and other as-yet-undefined mechanisms.
Finally, this study has confirmed the well-known asso-
ciation between corticosteroid use and hypercholester-
olemia [34,35]. This highlights the need for vigilant
monitoring of lipid levels in times of active disease and
during treatment with corticosteroids.
Future studies must be done to quantify the CAD risk
associated with corticosteroid dose. Future studies will
also need to determine the relation between various lip-
ids and lipoproteins, such as high- and low-density lipo-
protein cholesterol (HDL-C and LDL-C) over time in
SLE. Lack of a large number of serial measurements of
these lipid and lipoprotein fractions among our patients
precluded us from doing such an analysis in the present
study.
The contributions of this study to the field of SLE-
related CAD are both conceptual and practical. First, this
study has illustrated a very important concept: the
marked variability of T C and BP over time in patients
with SLE. The dynamic nature of these variables, in
patients with SLE, makes a strong case for deriving sum-
mary measures that better capture cumulative exposure
to these risk factors over time, than a single-point-in-time
or 'snap-shot' measurement. Use of such cumulative mea-
sures would allow more-accurate quantification of risk
for CAD in SLE. Second, this study has provided some
insights into the complex relation between various risk
factors for CAD in SLE. However, these interactions
merit further investigation in longitudinal studies.
Conclusions
This study has shown that TC, SBP, and DBP take a
dynamic course in SLE, with more than half of the total
variance over time seen within individual patients. Here
we have shown that these risk factors fluctuate because of
changes in disease activity, medications, and the accrual
of other cardiovascular risk factors. The variable nature
of cholesterol and blood pressure in patients with SLE
makes a compelling case for deriving summary measures
that better capture cumulative exposure to these risk fac-
tors over time.
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